A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer

Primary Objective: \- To determine the Progression Free Survival (PFS) in patients with metastatic breast cancer after treatment with taxane plus bevacizumab with (TXB) or without capecitabine (TB). Secondary Objective(s): * To determine the objective response rate in both arms. * To determine the duration of response in both arms. * To determine the Time to Progression (TTP) in both arms. * To determine the clinical benefit defined as CR, PR, or stable disease ≥ 24 weeks in both arms. * To determine the overall survival rate 3 years after "Last Patient In". * To determine PFS and TTP response rates in patient's ≥ age 65. * To determine the toxicity and compliance in both arms. * To determine the predictive value of serum markers such as VEGF.